Scancell Appoints Sath Nirmalananthan as CFO

Scancell Holdings Plc

29 August 2023

 

            29 August 2023

Scancell Holdings plc

("Scancell" or the "Company")

Scancell Appoints Sath Nirmalananthan as Chief Financial Officer

Keith Green to retire as Director of Finance but to remain as Company Secretary

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces the appointment of Sath Nirmalananthan as Chief Financial Officer (CFO), with immediate effect.

Sath Nirmalananthan is an experienced finance professional with over 15 years experience across healthcare in FTSE and NASDAQ listed companies, investment banking and audit. Before joining Scancell, Sath was Chief Financial Officer for Europe, Middle-East and Africa at Prenetics, a leading genomics-driven health sciences company. Prior to that, Sath worked at Reckitt where he was Finance Director for Group Reporting and subsequently for eCommerce in Reckitt's Health Division. Sath has also held senior positions at BTG plc, a specialty pharmaceutical company, including Director of Group Reporting and Director of FP&A of interventional oncology. Earlier in his career, he was an equity research analyst in the healthcare team at Nomura and prior to that an auditor at KPMG. Sath earned a BSc in Pharmacology from King's College, London, UK and holds an ACA (ICAEW), Chartered Accountant qualification. Sath is also a Non-Executive member of the audit committee at The Institute of Cancer Research (ICR).

Prof Lindy Durrant, Chief Executive Officer of Scancell, commented: "We are excited to have Sath join us as Chief Financial Officer. His financial acumen and extensive track record of building value in emerging biopharmaceutical companies will benefit Scancell in our next stage of evolution. I look forward to working with him closely as we continue to focus the clinical development of our two lead cancer vaccine assets, SCIB1 and Modi-1, whilst continuing to leverage the potential of our proprietary antibody platform through additional licensing and revenue generating opportunities. We are very grateful for Keith's excellent financial guidance which has been invaluable to Scancell's success to date and are pleased that he will continue as Company Secretary."

Commenting on his appointment as Chief Financial Officer, Sath Nirmalananthan said: "I am excited to be joining Scancell at such a pivotal time. With the Phase 2 single arm SCOPE trial progressing and initial topline data readouts expected this year and Modi-1 next year, the Company is positioned with highly valuable science and near-term inflection points that should deliver value to our shareholders. I look forward to working with Lindy and the wider team and am excited by the potential of what can be achieved."

For further information, please contact:
Scancell Holdings plc	[phone]
Professor Lindy Durrant, CEO Dr Jean-Michel Cosséry, Non-Executive Chairman
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)	[phone]
Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)
Panmure Gordon (UK) Limited (Joint Broker)	[phone]
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications	[phone]
Mary-Jane Elliott/Matthew Neal/Chris Welsh	[e-mail]

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope^® and ImmunoBody^® for vaccines and GlyMab^® and AvidiMab^® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope^® and ImmunoBody^®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab^®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab^®).

For further information about Scancell, please visit: https://www.scancell.co.uk/

 

END